DECN Adds International Distribution for its Genultimate, Genchoice, Genprecis and Gensure Products

DECN’s Panacea Genultimate TBG Product will be Handled Internationally by a Single Mega-Distributor as Talks Reach Conclusion Stage

LOS ANGELES, CA / ACCESSWIRE / September 4, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! (“Sunshine”) diabetes test strip, the internationally sold GenSure! (“Feather”) diabetes test strip, and its GenChoice! (“Ladybug”) test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses that has been licensed to Fetch 4Pets, and the panacea GenUltimate! TBG (“Dragonfly”) diabetes testing system, now awaiting a clinical trial slot in Korea.

DECN announces that they have solicited distribution agreements with distributors located in the following international countries:

  • Russian Federation (distributor chosen, distribution tentatively filled)
  • Post Brexit United Kingdom
  • Canada
  • India
  • Mexico, Central America and South America
  • South Africa

Discussions currently are currently focused on the company’s GenUltimate, GenChoice, GenPrecis and GenSure products. DECN will have more to say about its panacea GenUltimate TBG, which will be distributed internationally by a mega-distribution organization. Discussions for GenUltimate TBG are nearly complete. A large Russian based distributor is deep into talks and is expected to execute a distribution contract shortly. In addition DECN has received written requests from Mexico, South Africa and India.

Keith Berman, CEO of DECN commented, “We anticipate international sales to make up a significant portion of our overall sales in 2020. All of the contacts we are currently working on are from international organizations who contacted us once a legacy manufacturer pulled their similar products out of the international channels. We will attempt to fill in the gaps in those countries where we can make immediate impact.”

Mr. Berman continued, “Our GenUltimate TBG product will also be sold internationally, and sales will begin as soon as our Precise meter is complete. The Precise meter is what makes GenUltimate TBG so unique. GenUltimate TBG will be sold by a single mega-distributor who will treat our panacea product as if it were a legacy product. The launch GenUltimate TBG will complete the first part of our product branding.


Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market.

Forward-Looking Statements:

This release contains the company’s forward-looking statements which are based on management’s current expectations and assumptions as of September 3, 2019, regarding the company’s business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.


Decision Diagnostics Corp.
Keith Berman (805) 446-2973

SOURCE: Decision Diagnostics Corp.

View source version on

error: Content is protected !!